Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate
- PMID: 2140282
- DOI: 10.1111/j.1464-410x.1990.tb14759.x
Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate
Abstract
Orchiectomy was performed in 16 patients because of progression of prostatic cancer despite adequate medical castration with goserelin (Zoladex, ICI) over a mean period of 17.6 months. Severe tubular atrophy was seen in the testes. The Leydig cells also showed signs of atrophy, a fact that may indicate a direct effect of goserelin on these cells. In 1 patient, however, orchiectomy was postponed for 3 months after cessation of medical castration. The serum testosterone had resumed almost normal values and testicular histology revealed intact spermatogenesis and apparently normal Leydig cells.
Similar articles
-
U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.Am J Clin Oncol. 1988;11 Suppl 2:S169-72. doi: 10.1097/00000421-198801102-00039. Am J Clin Oncol. 1988. PMID: 2977272 Clinical Trial.
-
[Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].Wien Klin Wochenschr. 1990 Nov 9;102(21):640-7. Wien Klin Wochenschr. 1990. PMID: 2148044 German.
-
Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.Urology. 1991 Jan;37(1):17-21. doi: 10.1016/0090-4295(91)80070-n. Urology. 1991. PMID: 1702566
-
Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.Br J Urol. 1986 Oct;58(5):539-44. doi: 10.1111/j.1464-410x.1986.tb05463.x. Br J Urol. 1986. PMID: 2946356
-
Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.Cancer Res. 1990 Feb 1;50(3):568-74. Cancer Res. 1990. PMID: 2137024
Cited by
-
Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer.Urol Case Rep. 2017 Apr 19;13:48-50. doi: 10.1016/j.eucr.2017.03.027. eCollection 2017 Jul. Urol Case Rep. 2017. PMID: 28443242 Free PMC article.
-
Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.Investig Clin Urol. 2018 Jan;59(1):18-24. doi: 10.4111/icu.2018.59.1.18. Epub 2017 Dec 20. Investig Clin Urol. 2018. PMID: 29333510 Free PMC article.
-
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007. Drugs Aging. 1995. PMID: 7613021 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical